Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+status: Updated results from the phase 3 IKEMA study.

被引：0

作者：

Facon, Thierry

Moreau, Philippe

Spicka, Ivan

Suzuki, Kenshi

Yong, Kwee

Mikhael, Joseph

Fukao, Taro

Bisht, Kamlesh

Armstrong, Nicole

Mace, Sandrine

Risse, Marie-Laure

Martin, Thomas G.

机构：

[1] Lille Univ Hosp, Dept Hematol, Lille, France

[2] Univ Hosp Nantes, Dept Hematol, Nantes, France

[3] Charles Univ Prague, Gen Fac Hosp, Prague, Czech Republic

[4] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[5] Japanese Red Cross Med Ctr, Myeloma Amyloidosis Ctr, Tokyo, Japan

[6] Univ Coll Hosp, Dept Haematol, London, England

[7] City Hope Canc Ctr, Translat Genom Res Inst, Appl Canc Res & Drug Discovery, Phoenix, AZ USA

[8] Sanofi, Global Oncol, Cambridge, MA USA

[9] Sanofi, Global Med Affairs, Cambridge, MA USA

[10] Sanofi, Res & Dev, Chilly Mazarin, France

[11] Sanofi, Res & Dev, Vitry Sur Seine, France

[12] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8029

引用

页数：1

共 50 条

[41] Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1
Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf-Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordstrom, Eva
Harmenberg, Johan
Obermuller, Jakob
Richardson, Paul G.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (06) : 1105 - 1109
[42] Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Douvali, Maria
Psarros, Giorgos
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2023, 142
[43] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Rasche, Leo
Schinke, Carolina
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Ye, Jing Christine
Vishwamitra, Deeksha
Singh, Indrajeet
Qin, Xiang
Campagna, Michela
Masterson, Tara
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
[44] Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study
Chari, Ajai
Usmani, Saad Z.
Krishnan, Amrita
Lonial, Sagar
Comenzo, Raymond
Wu, Kaida
Wang, Jianping
Doshi, Parul
Weiss, Brendan M.
Schecter, Jordan
Jakubowiak, Andrzej J.
BLOOD, 2017, 130
[45] Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study
Weisel, Katja
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Cocks, Kim
Espensen, Ashlee
Popa-McKiver, Mihaela
Chen, Clara
Cavo, Michele
BLOOD, 2018, 132
[46] FINAL RESULTS FROM THE PHASE 1B/2 STUDY (PX-171-006) OF CARFILZOMIB (CFZ) IN COMBINATION WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (CRD) FOR PATIENTS WITH RELAPSED OR PROGRESSIVE MULTIPLE MYELOMA
Niesvizky, R.
Wang, M.
Martin, T.
Bensinger, W.
Alsina, M.
Siegel, D.
Kavalerchik, E.
HAEMATOLOGICA, 2013, 98 : 242 - 242
[47] Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety
Lonial, Sagar
Jagannath, Sundar
Moreau, Philippe
Jakubowiak, Andrzej J.
Raab, Marc S.
Facon, Thierry
Vij, Ravi
Bleickardt, Eric
Reece, Donna Ellen
Benboubker, Lotfi
Zonder, Jeffrey A.
Deng, Wei
Singhal, Anil K.
Richardson, Paul Gerard Guy
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[48] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
Hari, P.
Shain, K. H.
Voorhees, P.
Gabrail, N.
Abidi, M.
Zonder, J.
Boccia, R.
Richardson, P. G.
Neuman, L.
Wong, H.
Dixon, S.
Prada, C. P.
HAEMATOLOGICA, 2015, 100 : 254 - 255
[49] Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf-Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordstrom, Eva
Harmenberg, Johan
Obermueller, Jakob
Richardson, Paul G.
BLOOD, 2019, 134
[50] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Popat, Rakesh
Usmani, Saad Z.
Garfall, Alfred
van de Donk, Niels
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar
Moreau, Philippe
Besemer, Britta
Martinez-Lopez, Joaquin
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36

← 1 2 3 4 5 →